MedPath

Scioto Biosciences, Inc.

Scioto Biosciences, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2017-01-01
Employees
11
Market Cap
-
Website
http://www.sciotobiosciences.com

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder

Phase 1
Completed
Conditions
Autistic Disorder
Interventions
Drug: Placebo
First Posted Date
2021-06-30
Last Posted Date
2024-03-25
Lead Sponsor
Scioto Biosciences, Inc.
Target Recruit Count
15
Registration Number
NCT04944901
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.